---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-046115"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:31:31.374010+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line

## Summary
- FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.
- Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.
- Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.
- Existing credit facilities also extended; company expects funding through at least March 2027.

## SEC filing metadata
- accession: 0001140361-25-046115
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/0001140361-25-046115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/ef20061484_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-046115
- JSON: https://secwatch.observer/filing/0001140361-25-046115.json
- Plain text: https://secwatch.observer/filing/0001140361-25-046115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.